Search hospitals > Nebraska > Lincoln
Nebraska Hematology and Oncology
Claim this profileLincoln, Nebraska 68506
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Lymphoma
99 reported clinical trials
3 medical researchers
Summary
Nebraska Hematology and Oncology is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Nebraska Hematology and Oncology is involved with conducting 99 clinical trials across 148 conditions. There are 3 research doctors associated with this hospital, such as Ralph Hauke, MD, Kailash Mosalpuria, and Irfan Vaziri.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage I
Stage II
Top PIs
Ralph Hauke, MDNebraska Cancer Specialists2 years of reported clinical research
Expert in Skin Cancer
Expert in Prostate Cancer
36 reported clinical trials
74 drugs studied
Kailash MosalpuriaNebraska Hematology-Oncology, P.C.2 years of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
6 reported clinical trials
13 drugs studied
Irfan VaziriNebraska Hematology - Oncology, P.C.3 years of reported clinical research
Studies Plasma Cell Neoplasm
Studies Multiple Myeloma
1 reported clinical trial
4 drugs studied
Clinical Trials running at Nebraska Hematology and Oncology
Lung Cancer
Non-Small Cell Lung Cancer
Breast Cancer
Myelofibrosis
Oral Cancers
Laryngeal Cancer
Oropharyngeal Carcinoma
Skin Cancer
ALK Gene Rearrangement
Multiple Myeloma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Telisotuzumab Vedotin vs. Docetaxel
for Non-Small Cell Lung Cancer
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting2 awards Phase 312 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Nebraska Hematology and Oncology?
Nebraska Hematology and Oncology is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Skin Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Lymphoma and other specialties. Nebraska Hematology and Oncology is involved with conducting 99 clinical trials across 148 conditions. There are 3 research doctors associated with this hospital, such as Ralph Hauke, MD, Kailash Mosalpuria, and Irfan Vaziri.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.